This approval came after Novo Nordisk's Saxenda formulation demonstrated efficacy in reducing body weight by an average of 1015% in clinical trials
Combining the two requires medical supervision for appropriate dosing and monitoring
The typical tall cell tumour is greater than 5 cm in size on presentation, has extrathyroidal and vascular invasion in 54% of cases, but a 5-year survival rate of around 80%
In recent years, we have witnessed a paradigm shift in cardiometabolic medicine: The SELECT trial demonstrated that GLP-1 receptor agonists reduce cardiovascular events even in patients without diabetes
Cancer 75 , 589592 (1997)
Weekly injections of semaglutide, combined with lifestyle changes, have shown significant results, with many patients losing nearly 15% of their body fat over time